CPS1
Basic information
Region (hg38): 2:210477682-210679107
Links
Phenotypes
GenCC
Source:
- carbamoyl phosphate synthetase I deficiency disease (Definitive), mode of inheritance: AR
- carbamoyl phosphate synthetase I deficiency disease (Definitive), mode of inheritance: AR
- carbamoyl phosphate synthetase I deficiency disease (Strong), mode of inheritance: AR
- carbamoyl phosphate synthetase I deficiency disease (Supportive), mode of inheritance: AR
- carbamoyl phosphate synthetase I deficiency disease (Definitive), mode of inheritance: AR
Clinical Genomic Database
Source:
Condition | Inheritance | Intervention Categories | Intervention/Rationale | Manifestation Categories | References |
---|---|---|---|---|---|
Carbamoylphosphate synthetase I deficiency | AR | Biochemical; Pharmacogenomic | Specific urgent and long-term medical management (eg, dietary measures, arginine, sodium benzoate, sodium phenylbutyrate), as well as measures such as dialysis when necessary, may be beneficial to reduce morbidity and mortality; Avoidance of certain agents (eg, valproate), as well as special considerations in situations such as peregnancy, are warranted due to potential adverse events | Biochemical; Neurologic | 5356974; 5471650; 4111816; 4811018; 7078580; 6427608; 3759432; 3792387; 1414247; 8486760; 8273985; 9711878; 21120950; 16708072; 17310273; 19793055; 21120950; 22173106; 25135652; 25410056 |
ClinVar
This is a list of variants' phenotypes submitted to
- Congenital hyperammonemia, type I (84 variants)
- Pulmonary hypertension, neonatal, susceptibility to (17 variants)
- not provided (2 variants)
- Congenital hyperammonemia, type I;Pulmonary hypertension, neonatal, susceptibility to (1 variants)
- Inborn genetic diseases (1 variants)
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the CPS1 gene is commonly pathogenic or not.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Variant type | Pathogenic | Likely pathogenic | VUS | Likely benign | Benign | Sum |
---|---|---|---|---|---|---|
synonymous | 532 | 538 | ||||
missense | 34 | 271 | 46 | 10 | 366 | |
nonsense | 32 | 65 | 98 | |||
start loss | 3 | |||||
frameshift | 44 | 57 | 101 | |||
inframe indel | 9 | |||||
splice donor/acceptor (+/-2bp) | 61 | 72 | ||||
splice region | 4 | 28 | 115 | 10 | 157 | |
non coding | 23 | 347 | 95 | 465 | ||
Total | 92 | 220 | 303 | 925 | 112 |
Highest pathogenic variant AF is 0.0000330
Variants in CPS1
This is a list of pathogenic ClinVar variants found in the CPS1 region.
You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.
Position | Type | Phenotype | Significance | ClinVar |
---|---|---|---|---|
2-210477693-A-ATAGTTGCTTTCTTAGGAAATG | not specified | Likely benign (Jun 28, 2016) | ||
2-210477748-G-A | not specified | Benign (Mar 14, 2016) | ||
2-210477765-T-G | Congenital hyperammonemia, type I | Uncertain significance (Dec 04, 2017) | ||
2-210477778-G-A | not specified • Congenital hyperammonemia, type I | Benign (Jul 10, 2021) | ||
2-210556381-G-T | Likely benign (Jan 09, 2020) | |||
2-210556398-C-A | Benign (Oct 08, 2020) | |||
2-210556540-G-A | Benign (Oct 17, 2018) | |||
2-210556606-G-A | Congenital hyperammonemia, type I | Likely benign (Jan 16, 2019) | ||
2-210556658-A-G | Congenital hyperammonemia, type I | Uncertain significance (Jan 13, 2018) | ||
2-210556705-T-G | Congenital hyperammonemia, type I • not specified • CPS1-related disorder | Benign (Jan 13, 2018) | ||
2-210556728-A-ATCT | not specified • Congenital hyperammonemia, type I | Benign (Jul 30, 2021) | ||
2-210556730-C-A | Congenital hyperammonemia, type I • CPS1-related disorder | Uncertain significance (Jan 12, 2018) | ||
2-210556731-A-TTCC | Congenital hyperammonemia, type I | Uncertain significance (Dec 01, 2017) | ||
2-210556736-G-T | Congenital hyperammonemia, type I | Likely pathogenic (Sep 26, 2017) | ||
2-210556738-C-T | Congenital hyperammonemia, type I • Inborn genetic diseases | Conflicting classifications of pathogenicity (Jan 29, 2024) | ||
2-210556739-G-A | Congenital hyperammonemia, type I | Likely benign (Jan 29, 2024) | ||
2-210556741-G-T | Congenital hyperammonemia, type I | Uncertain significance (Jun 16, 2022) | ||
2-210556742-G-A | Congenital hyperammonemia, type I | Likely benign (Jun 03, 2021) | ||
2-210556748-G-C | Congenital hyperammonemia, type I | Uncertain significance (Aug 13, 2020) | ||
2-210556750-C-T | Congenital hyperammonemia, type I | Likely benign (Feb 11, 2023) | ||
2-210556751-A-G | Congenital hyperammonemia, type I | Likely benign (Jun 05, 2023) | ||
2-210556758-A-T | Congenital hyperammonemia, type I | Pathogenic/Likely pathogenic (Jan 16, 2024) | ||
2-210556760-A-G | Congenital hyperammonemia, type I | Likely benign (Mar 07, 2023) | ||
2-210556766-G-A | Congenital hyperammonemia, type I | Likely benign (Dec 06, 2020) | ||
2-210556772-A-C | Congenital hyperammonemia, type I | Likely benign (May 21, 2021) |
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
CPS1 | protein_coding | protein_coding | ENST00000430249 | 39 | 201426 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
1.09e-9 | 1.00 | 125680 | 0 | 68 | 125748 | 0.000270 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | 1.46 | 681 | 797 | 0.854 | 0.0000417 | 9875 |
Missense in Polyphen | 231 | 315.4 | 0.7324 | 3872 | ||
Synonymous | -1.29 | 309 | 281 | 1.10 | 0.0000146 | 2928 |
Loss of Function | 5.08 | 30 | 78.7 | 0.381 | 0.00000388 | 981 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.000239 | 0.000239 |
Ashkenazi Jewish | 0.000198 | 0.000198 |
East Asian | 0.000435 | 0.000435 |
Finnish | 0.000323 | 0.000323 |
European (Non-Finnish) | 0.000344 | 0.000316 |
Middle Eastern | 0.000435 | 0.000435 |
South Asian | 0.000196 | 0.000196 |
Other | 0.000491 | 0.000489 |
dbNSFP
Source:
- Function
- FUNCTION: Involved in the urea cycle of ureotelic animals where the enzyme plays an important role in removing excess ammonia from the cell.;
- Disease
- DISEASE: Carbamoyl phosphate synthetase 1 deficiency (CPS1D) [MIM:237300]: An autosomal recessive disorder of the urea cycle causing hyperammonemia. It can present as a devastating metabolic disease dominated by severe hyperammonemia in neonates or as a more insidious late-onset condition, generally manifesting as life-threatening hyperammonemic crises under catabolic situations. Clinical features include protein intolerance, intermittent ataxia, seizures, lethargy, developmental delay and mental retardation. {ECO:0000269|PubMed:11388595, ECO:0000269|PubMed:11474210, ECO:0000269|PubMed:12655559, ECO:0000269|PubMed:12955727, ECO:0000269|PubMed:15164414, ECO:0000269|PubMed:15617192, ECO:0000269|PubMed:16737834, ECO:0000269|PubMed:17310273, ECO:0000269|PubMed:20578160, ECO:0000269|PubMed:21120950, ECO:0000269|PubMed:22173106, ECO:0000269|PubMed:23649895, ECO:0000269|PubMed:24813853, ECO:0000269|PubMed:26440671, ECO:0000269|PubMed:9711878}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Pulmonary hypertension, neonatal (PHN) [MIM:615371]: A disease characterized by elevated pulmonary artery pressure. Pulmonary hypertension in the neonate is associated with multiple underlying problems such as respiratory distress syndrome, meconium aspiration syndrome, congenital diaphragmatic hernia, bronchopulmonary dysplasia, sepsis, or congenital heart disease. {ECO:0000269|PubMed:11407344}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry. CPS1 variants influence the availability of precursors for nitric oxide (NO) synthesis and play a role in clinical situations where endogenous NO production is critically important, such as neonatal pulmonary hypertension, increased pulmonary artery pressure following surgical repair of congenital heart defects or hepatovenocclusive disease following bone marrow transplantation. Infants with neonatal pulmonary hypertension homozygous for Thr- 1406 have lower L-arginine concentrations than neonates homozygous for Asn-1406 (PubMed:11407344). {ECO:0000269|PubMed:11407344}.;
- Pathway
- Alanine, aspartate and glutamate metabolism - Homo sapiens (human);Nitrogen metabolism - Homo sapiens (human);Arginine biosynthesis - Homo sapiens (human);Argininemia;2-Hydroxyglutric Aciduria (D And L Form);Hyperornithinemia with gyrate atrophy (HOGA);Creatine deficiency, guanidinoacetate methyltransferase deficiency;L-arginine:glycine amidinotransferase deficiency;Hyperornithinemia-hyperammonemia-homocitrullinuria [HHH-syndrome];Guanidinoacetate Methyltransferase Deficiency (GAMT Deficiency);Ammonia Recycling;Citrullinemia Type I;Carbamoyl Phosphate Synthetase Deficiency;Argininosuccinic Aciduria;Urea Cycle;Homocarnosinosis;Hyperinsulinism-Hyperammonemia Syndrome;Succinic semialdehyde dehydrogenase deficiency;Prolinemia Type II;Prolidase Deficiency (PD);Ornithine Transcarbamylase Deficiency (OTC Deficiency);Arginine and Proline Metabolism;4-Hydroxybutyric Aciduria/Succinic Semialdehyde Dehydrogenase Deficiency;Hyperprolinemia Type I;Hyperprolinemia Type II;Ornithine Aminotransferase Deficiency (OAT Deficiency);Arginine: Glycine Amidinotransferase Deficiency (AGAT Deficiency);Glutamate Metabolism;Amino Acid metabolism;Urea cycle and metabolism of amino groups;Glutamate Glutamine metabolism;Metabolism of polyamines;Metabolism of amino acids and derivatives;Metabolism;Urea cycle and metabolism of arginine, proline, glutamate, aspartate and asparagine;urea cycle;Pyrimidine nucleotides nucleosides metabolism;Urea cycle
(Consensus)
Recessive Scores
- pRec
- 0.264
Intolerance Scores
- loftool
- 0.0148
- rvis_EVS
- -0.63
- rvis_percentile_EVS
- 16.81
Haploinsufficiency Scores
- pHI
- 0.704
- hipred
- Y
- hipred_score
- 0.698
- ghis
- 0.466
Essentials
- essential_gene_CRISPR
- N
- essential_gene_CRISPR2
- N
- essential_gene_gene_trap
- N
- gene_indispensability_pred
- E
- gene_indispensability_score
- 0.980
Gene Damage Prediction
All | Recessive | Dominant | |
---|---|---|---|
Mendelian | High | High | High |
Primary Immunodeficiency | High | High | High |
Cancer | High | High | High |
Mouse Genome Informatics
- Gene name
- Cps1
- Phenotype
- homeostasis/metabolism phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span);
Zebrafish Information Network
- Gene name
- cps1
- Affected structure
- urea cycle
- Phenotype tag
- abnormal
- Phenotype quality
- disrupted
Gene ontology
- Biological process
- urea cycle;proteolysis;arginine biosynthetic process;nitrogen compound metabolic process;midgut development;response to zinc ion;response to amine;citrulline biosynthetic process;triglyceride catabolic process;response to food;response to lipopolysaccharide;vasodilation;response to starvation;response to amino acid;cellular response to fibroblast growth factor stimulus;nitric oxide metabolic process;homocysteine metabolic process;anion homeostasis;response to growth hormone;hepatocyte differentiation;carbamoyl phosphate biosynthetic process;cellular response to glucagon stimulus;cellular response to oleic acid;response to dexamethasone;cellular response to ammonia
- Cellular component
- nucleolus;cytoplasm;mitochondrial inner membrane;mitochondrial matrix;protein-containing complex;mitochondrial nucleoid
- Molecular function
- carbamoyl-phosphate synthase (ammonia) activity;endopeptidase activity;calcium ion binding;protein binding;ATP binding;phospholipid binding;glutamate binding;protein-containing complex binding;modified amino acid binding